Research & Clinical Community
Our proposal brings together internationally recognised leaders in childhood arthritis, JIA-uveitis, and bioinformatics, with industry, patient and clinical partners, as the CLUSTER consortium. Our goal is to define distinct ‘endotypes’ or ‘strata’ of childhood arthritis and JIA-uveitis, reflecting treatment response and disease course; integrate these with prognostic biomarkers; generate stratification algorithms, facilitate targeted treatment choices and propose new therapies.
CLUSTER partnerships with industry, patients, clinicians, and leading JIA experts, are established nationally and internationally, enabling us to replicate new findings, introduce biomarkers into clinical trials, and implement stratified approaches through the NHS.
Data Access
Access to CLUSTER data is regulated according to the conditions of patient consent and study ethics. Access it available for bona fide researchers via an application to the CLUSTER data access committee. Please make any initial enquiries for data access via our contact email address clusterconsortium@ucl.ac.uk
TranSMART
TranSMART is a web-based knowledge management platform that enables the safe hosting, management and data-sharing across the CLUSTER consortium. TranSMART allows for queries, exploration and analysis of clinical, genetic, genomic and transnational data.
TranSMART enables integrated analysis towards the identification of biomarker signatures that will help researchers and clinicians better understand the different responses to biologic drugs that are seen in the clinic, ultimately offering better and more personalised treatment to those affected by JIA-Arthritis and JIA-Uveitis.
The TranSMART platform, is widely used internationally for translational research (http://transmartfoundation.org/). For more information regarding TranSMART please contact the CLUSTER Consortium at clusterconsortium@ucl.ac.uk
CLUSTER and FAIR Data Principles
Our Consortium follows FAIR (Findable, Accessible, Interoperable, Reproducible) principles for data sharing, data and sample access: www.go-fair.org/fair-principles. Our CLUSTER website will share consortium publications throughout the life of the project and SOP definitions, data access and sharing policies are available on request.
We plan to publish in a timely manner, in the highest impact journals, with open access. All project data and metadata will be made available to the scientific community when possible. Further to this CLUSTER will be aligning with standards and SOPs adopted by the IMID-Bio-UK consortium, with a view towards future sample and data sharing with this consortium.
2020, FAIR Principles, PaNOSC, 16/06/21<https://www.panosc.eu/data/fair-principles/>
CLUSTER Research & Industry Event
CLUSTER aims to run a series of learning seminars aimed to provide understanding of how machine-learning can be utilised in complex datasets, and its utilisation within the CLUSTER Consortium. One of CLUSTERs aims is defining disease strata based on both long-term prognosis and treatment response using novel data-driven analytical approaches.
Our next Digital Seminar date and speaker is to be confirmed. Please check back here another time or follow our twitter @CLUSTER_Tweet for updates
Most recent seminar: Monday 18th October 2021, 15:45-16:30 (BST)
Speaker: Dr Jie Zheng
Talk Title: ‘Platelet Glycoprotein Ib α-Chain as a Putative Therapeutic Target for Juvenile Idiopathic Arthritis: evidence from a genetic epidemiology study’
Missed this seminar? Please see the link and password below to watch the recording:
|
Topic |
Password |
|
qUP9XgYJ |
Please contact Teresa.duerr@uhbw.nhs.uk with any queries regarding the seminar series.
FAQ
Q1: Who Do I Contact About Research Opportunities and Collaborations?
Q2: Where Can I Find Out About CLUSTER Outputs?
To find out the latest information on CLUSTER outputs, research papers, events and more, subscribe to the Mailing List below.
Mailing List Sign Up
Join the CLUSTER Mailing List
Joining the CLUSTER mailing list is best way to stay informed about everything we are doing, the latest research findings, news and events and Industry partnerships.
We won't bombard you, and we will protect your data and privacy.